To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question
Authors
Keywords
-
Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages 101869
Publisher
Elsevier BV
Online
2023-08-30
DOI
10.1016/j.berh.2023.101869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial
- (2023) L Uhrenholt et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Looking Through the Window of Opportunity in Axial Spondyloarthritis?
- (2023) Diego Benavent et al. JOINT BONE SPINE
- Factors associated with drug-free remission at 5 year in early onset axial spondyloarthritis patients: data from the DESIR cohort
- (2022) Adeline Ruyssen-Witrand et al. JOINT BONE SPINE
- Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
- (2022) J Ruwaard et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
- (2022) Celia AJ Michielsens et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
- (2022) Murat Torgutalp et al. ANNALS OF THE RHEUMATIC DISEASES
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
- (2022) Laura C. Coates et al. Nature Reviews Rheumatology
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- (2022) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
- (2022) Casper Webers et al. ANNALS OF THE RHEUMATIC DISEASES
- Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
- (2021) Robert BM Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- Twenty years of clinical trials in axial spondyloarthritis
- (2021) Joachim Sieper et al. CURRENT OPINION IN RHEUMATOLOGY
- Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
- (2021) Daniele Mauro et al. Nature Reviews Rheumatology
- Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
- (2021) A. Prior-Español et al. Scientific Reports
- Axial spondyloarthritis
- (2021) Victoria Navarro-Compán et al. ANNALS OF THE RHEUMATIC DISEASES
- Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis
- (2021) Ann-Sophie De Craemer et al. RHEUMATOLOGY
- Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations
- (2021) Félicie Costantino et al. RHEUMATOLOGY
- Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
- (2021) Celia A J Michielsens et al. RHEUMATOLOGY
- Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis
- (2021) Line Uhrenholt et al. RHEUMATOLOGY
- Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
- (2020) Celia A. J. Michielsens et al. Trials
- Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
- (2020) Robert BM Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- (2020) Laure Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment strategies in axial spondyloarthritis: what, when and how?
- (2020) George E Fragoulis et al. RHEUMATOLOGY
- Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis
- (2020) Frank Penkava et al. Nature Communications
- Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
- (2020) Silvia Menegatti et al. ANNALS OF THE RHEUMATIC DISEASES
- Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
- (2019) Line Uhrenholt et al. BMJ Open
- High rate of drug-free remission after induction therapy with golimumab in early peripheral spondyloarthritis
- (2018) Philippe Carron et al. Arthritis & Rheumatology
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
- (2018) Dominique Baeten et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
- (2018) Loredana Frasca et al. Frontiers in Immunology
- Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?
- (2018) D Wallis et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
- (2017) Lieke Tweehuysen et al. Arthritis & Rheumatology
- Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population
- (2016) Jitian Li et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis
- (2016) Xenofon Baraliakos et al. RHEUMATOLOGY
- Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial
- (2015) M. Yates et al. JOURNAL OF RHEUMATOLOGY
- Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort
- (2015) Jeffrey D. Greenberg et al. JOURNAL OF RHEUMATOLOGY
- Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial
- (2014) I.-H. Song et al. JOURNAL OF RHEUMATOLOGY
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis
- (2013) Jacqueline E Paramarta et al. ANNALS OF THE RHEUMATIC DISEASES
- Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis
- (2013) Carmen Stolwijk et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare
- (2013) H. Haibel et al. ARTHRITIS AND RHEUMATISM
- Burden of treatment for chronic illness: a concept analysis and review of the literature
- (2013) Adem Sav et al. HEALTH EXPECTATIONS
- Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial
- (2012) In-Ho Song et al. ANNALS OF THE RHEUMATIC DISEASES
- Dosage Adjustment of Anti-Tumor Necrosis Factor-α Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice
- (2012) JULIEN PACCOU et al. JOURNAL OF RHEUMATOLOGY
- The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
- (2011) N. B. Klarenbeek et al. ANNALS OF THE RHEUMATIC DISEASES
- The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
- (2010) M. Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis
- (2010) Jaejoon Lee et al. CLINICAL RHEUMATOLOGY
- Cost of Illness from the Public Payers' Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care
- (2010) B. STROMBECK et al. JOURNAL OF RHEUMATOLOGY
- Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis
- (2010) Denis Mulleman et al. THERAPEUTIC DRUG MONITORING
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
- (2009) M Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
- (2008) C Lukas et al. ANNALS OF THE RHEUMATIC DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started